Amplia Therapeutics Ltd logo

Amplia Therapeutics Ltd

NEW
ASX:ATX (Australia)  
A$ 0.14 (0%) Jun 26
At Loss
P/B:
1.74
Market Cap:
A$ 69.30M ($ 48.82M)
Enterprise V:
A$ 41.78M ($ 29.44M)
Volume:
1.54M
Avg Vol (2M):
1.13M
Trade In:
Volume:
1.54M
At Loss
Avg Vol (2M):
1.13M

Business Description

Description
Amplia Therapeutics Ltd is an Australian, clinical-stage, drug development company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. The company is focused on the development of these drug candidates for potential use in multiple indications in oncology (e.g. pancreatic cancer) and chronic fibrotic diseases. Its molecule, AMP945 is a selective and potent inhibitor of FAK and is currently in a phase 2 clinical trial for pancreatic cancer, in clinical development for ovarian cancer, and preclinical development for idiopathic pulmonary fibrosis (IPF).
Name Current Vs Industry Vs History
Cash-To-Debt
81.68
Equity-to-Asset
0.95
Debt-to-Equity
0.01
Debt-to-EBITDA
-0.05
Piotroski F-Score
2/9
0
1
2
3
4
5
6
7
8
9
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI
70.22
9-Day RSI
61.24
14-Day RSI
55
3-1 Month Momentum %
-34.78
6-1 Month Momentum %
20
12-1 Month Momentum %
-23.08

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio
19.79
Quick Ratio
19.79
Cash Ratio
16.68

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio
-36.1
Shareholder Yield %
-44.64
Name Current Vs Industry Vs History
ROE %
-22.36
ROA %
-21.23
ROIC %
-107.92
3-Year ROIIC %
-335
ROC (Joel Greenblatt) %
-354.21
ROCE %
-22.17
Moat Score
2
Tariff Resilience Score
6

Financials

ASX:ATX's 30-Y Financials
Income Statement Breakdown FY
Not Enough Data
Balance Sheet Breakdown
Not Enough Data
Cashflow Statement Breakdown
Not Enough Data

Operating Revenue by Business Segment

Operating Revenue by Geographic Region

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
Not Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2026
2025
2024
2023
2022
2021
2020
2019
2018
2017

Amplia Therapeutics Ltd Executives

Details

GF Valueâ„¢

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil A$)
EPS (TTM) (A$) -0.017
Beta -1.3578
3-Year Sharpe Ratio 0.49
3-Year Sortino Ratio 2.05
Volatility % 321.08
14-Day RSI 55
14-Day ATR (A$) 0.0136
20-Day SMA (A$) 0.119875
12-1 Month Momentum % -23.08
52-Week Range (A$) 0.1 - 0.425
Shares Outstanding (Mil) 513.31

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 2
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Amplia Therapeutics Ltd Filings

Filing Date Document Date Form
No Filing Data

Amplia Therapeutics Ltd Stock Events

Financials Calendars
Event Date Price (A$)
0.1:1 Stock Split 2018-04-30 0.37 (+0.00%)
Show
Entries

Amplia Therapeutics Ltd Frequently Asked Questions

What is Amplia Therapeutics Ltd(ASX:ATX)'s stock price today?
The current price of ASX:ATX is A$0.14. The 52 week high of ASX:ATX is A$0.43 and 52 week low is A$0.10.
When is next earnings date of Amplia Therapeutics Ltd(ASX:ATX)?
The next earnings date of Amplia Therapeutics Ltd(ASX:ATX) is .
Does Amplia Therapeutics Ltd(ASX:ATX) pay dividends? If so, how much?
Amplia Therapeutics Ltd(ASX:ATX) does not pay dividend.

Articles on Amplia Therapeutics Ltd

No articles.